Proactive Investors - Run By Investors For Investors

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
immune
Scancell makes selective immunotherapy agents that help the body overcome the immune suppression induced by tumours

Scancell Holdings PLC (LON:SCLP), the cancer immunotherapy specialist, has raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company when the shares are issued next Monday.

WATCH: Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment

Along with the stake in the company, Martin Diggle, co-founder of the fund’s owner, Vulpes Investment Management, and an experienced investor in the life science sector, has been proposed as a non-executive director.

Diggle, having conducted scientific and commercial due diligence on Scancell for some time, said Vulpes felt it was an “exciting time” in the evolution of the company, where he believed its “unique and innovative approach to fighting cancer is compelling and under-appreciated”.

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Scancell chairman John Chiplin said: “This new investment capital increases funds available to advance our product pipeline and in particular, the transition of our lead Moditope platform asset Modi-1 into the clinic.

Modi-1, part of a new class of selective immunotherapy agents that stimulate the production of killer T cells that overcome the immune suppression induced by tumours, is expected to enter the clinic in the first quarter of 2020 in multiple tumour types, including head and neck, breast and ovarian cancer.

Scancell shares were up almost 8% to 5.76p in early trading on Thursday.

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

picture of a knee
May 20 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
1557403923_iron.jpg
May 09 2019
Here we take a look under the hood of Shield Therapeutics
woman's face
Tue
Here we take a closer look at SkinBioTherapeutics, the life sciences group that is using bacteria to improve people’s skin

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use